Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,382 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer.
Ishiguro T, Sugimoto M, Kinoshita Y, Miyazaki Y, Nakano K, Tsunoda H, Sugo I, Ohizumi I, Aburatani H, Hamakubo T, Kodama T, Tsuchiya M, Yamada-Okabe H. Ishiguro T, et al. Among authors: sugimoto m. Cancer Res. 2008 Dec 1;68(23):9832-8. doi: 10.1158/0008-5472.CAN-08-1973. Cancer Res. 2008. PMID: 19047163
Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
Sano Y, Hashimoto E, Nakatani N, Abe M, Satoh Y, Sakata K, Fujii T, Fujimoto-Ouchi K, Sugimoto M, Nagahashi S, Aoki M, Motegi H, Sasaki E, Yatabe Y. Sano Y, et al. Among authors: sugimoto m. Mol Cancer Ther. 2015 Feb;14(2):533-41. doi: 10.1158/1535-7163.MCT-14-0456. Epub 2014 Dec 18. Mol Cancer Ther. 2015. PMID: 25522765
Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies.
Iwai T, Sugimoto M, Wakita D, Yorozu K, Kurasawa M, Yamamoto K. Iwai T, et al. Among authors: sugimoto m. Oncotarget. 2018 Jul 31;9(59):31411-31421. doi: 10.18632/oncotarget.25830. eCollection 2018 Jul 31. Oncotarget. 2018. PMID: 30140379 Free PMC article.
Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model.
Masuda C, Sugimoto M, Wakita D, Monnai M, Ishimaru C, Nakamura R, Kinoshita M, Yorozu K, Kurasawa M, Kondoh O, Yamamoto K. Masuda C, et al. Among authors: sugimoto m. Clin Exp Metastasis. 2020 Feb;37(1):199-207. doi: 10.1007/s10585-019-10008-z. Epub 2019 Nov 25. Clin Exp Metastasis. 2020. PMID: 31768815 Free PMC article.
2,382 results